Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?
- PMID: 18071720
- DOI: 10.1007/s00384-007-0408-6
Tumor response to neoadjuvant chemoradiation in rectal cancer: predictor for surgical morbidity?
Abstract
Background: Increasing the rate of pathological complete remissions after neoadjuvant chemoradiation of rectal cancer has become a strategy to further improve the long-term oncological outcome of patients. This report evaluates the influence of preoperative intensified radiochemotherapy on the rate and outcome of surgical complications.
Materials and methods: Patients with primary rectal cancer at stages cT3/4cNx or N+ without metastasis were preoperatively treated either with capecitabine and irinotecan or with capecitabine, irinotecan and ceutximab with a concurrent radiation (50.4 Gy). Surgery was scheduled 4-7 weeks after completion of the chemoradiation. Perioperative complications were prospectively documented during the patient's hospital stay.
Results: Fifty-nine patients (median age 60; male/female: 46/13) undergoing surgery at a single center were analysed. The median distance of the tumour from the dentate line was 5 cm. The operations performed were low anterior resection (n=45), Hartmann's procedure (n=4) and abdominoperineal resection (n=10). Total mesorectal excision with R0-resection was accomplished in all but one patients. Histopathological regression was described in four grades (0-3) as defined by the Japanese Society for Cancer of the Colon and Rectum. Tumors were called major responsive when assigned to the regression grades 3 or 2, and minor or nonresponsive at regression grades 1 or 0. In total, 33 patients (55.9%) had a regression grade 2 or 3. Among them, 12 patients showed a pathological complete response without any residual cancer cell (20.3%). Seven out of 45 patients (15.5%) with sphincter-preserving surgery suffered from suture breakdown; they all had previously shown a major response of the resected tumor. Two of them died during the hospital stay.
Conclusions: While in general, patients undergoing neoadjuvant intensified treatment suffer from a slight increase in surgical complications, this is markedly enhanced in patients with good treatment responses. Our results underline the oncological benefit of intensified neoadjuvant chemoradiation, but the severity of complications in low rectal anastomosis of patients with good response after neoadjuvant therapy should alert surgeons and oncologists.
Similar articles
-
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.Br J Cancer. 2007 Mar 26;96(6):912-7. doi: 10.1038/sj.bjc.6603645. Epub 2007 Feb 27. Br J Cancer. 2007. PMID: 17325705 Free PMC article. Clinical Trial.
-
[Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].Orv Hetil. 2006 Oct 22;147(42):2011-20. Orv Hetil. 2006. PMID: 17165600 Review. Hungarian.
-
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.Dis Colon Rectum. 2003 Apr;46(4):448-53. doi: 10.1007/s10350-004-6579-0. Dis Colon Rectum. 2003. PMID: 12682535
-
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.Strahlenther Onkol. 2008 Sep;184(9):450-6. doi: 10.1007/s00066-008-1751-4. Epub 2008 Sep 19. Strahlenther Onkol. 2008. PMID: 19016023 Clinical Trial.
-
Sphincter preservation therapy for rectal cancer.Clin Adv Hematol Oncol. 2003 Dec;1(12):735-40. Clin Adv Hematol Oncol. 2003. PMID: 16258478 Review.
Cited by
-
Preoperative treatment does not improve the therapeutic results of abdominosacral amputation of the rectum.World J Surg. 2012 Jul;36(7):1686-92. doi: 10.1007/s00268-012-1527-y. World J Surg. 2012. PMID: 22411086
-
Significant Pathologic Response Following Neoadjuvant Therapy and Curative Resection in Patients With Rectal Cancer: Surgical and Oncological Outcomes From a Retrospective Cohort Study.Cancer Rep (Hoboken). 2024 Nov;7(11):e70041. doi: 10.1002/cnr2.70041. Cancer Rep (Hoboken). 2024. PMID: 39506816 Free PMC article.
-
Short-term clinical outcomes of laparoscopic vs open rectal excision for rectal cancer: A systematic review and meta-analysis.World J Gastroenterol. 2017 Nov 28;23(44):7906-7916. doi: 10.3748/wjg.v23.i44.7906. World J Gastroenterol. 2017. PMID: 29209132 Free PMC article.
-
Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.World J Gastroenterol. 2016 Oct 7;22(37):8414-8434. doi: 10.3748/wjg.v22.i37.8414. World J Gastroenterol. 2016. PMID: 27729748 Free PMC article.
-
SEVTAR-A multicenter randomized controlled trial to investigate the impact of prophylactic endoluminal placed vacuum sponge for prevention of anastomotic leakage after low rectal resections.Front Surg. 2023 Feb 13;9:1099549. doi: 10.3389/fsurg.2022.1099549. eCollection 2022. Front Surg. 2023. PMID: 36860727 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical